## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($238.99)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Mark Cuban's Cost Plus Drugs, Humana exploring partnership to tackle employer drug costs**
- Source: Fierce Healthcare | 20251205T000827 | Bullish | Relevance: 100%
- Mark Cuban's Cost Plus Drugs and Humana are in discussions about a potential partnership aimed at reducing prescription drug costs for employers. This collaboration would leverage Humana's CenterWell healthcare services business to offer a direct-to-employer model for prescription drugs, effectively bypassing traditional pharmacy benefit managers. Both companies emphasize the need for transparency and simplification in the drug supply chain to deliver better value to consumers and employers.

**2. Humana Working With Mark Cuban on Potential Pharmacy Partnership**
- Source: Bloomberg Law News | 20251204T193744 | Somewhat-Bullish | Relevance: 100%
- Humana Inc. is exploring a potential pharmacy partnership with billionaire Mark Cuban's Cost Plus Drugs company, according to recent statements from Cuban and Humana's CEO. This collaboration could increase pressure on established pharmacy benefit managers. While details are scarce, the focus appears to be on direct-to-employer programs, leveraging Cuban's transparent mail-order drug sales and Humana's expanding CenterWell pharmacy division.

**3. Humana working with Mark Cuban on potential pharmacy partnership**
- Source: Modern Healthcare News | 20251204T145100 | Somewhat-Bullish | Relevance: 100%
- Humana is reportedly in discussions with Mark Cuban to develop direct-to-employer pharmacy programs. This partnership aims to streamline the drug supply chain by bypassing traditional intermediaries. The initiative could significantly impact how employers provide pharmaceutical benefits to their employees.

**4. Humana Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T163000 | Bullish | Relevance: 100%
- Humana Inc. (HUM) stock experienced a significant rise of 6.18% on a strong trading day for the overall stock market. This increase to $256.92 broke a three-day losing streak for the company. The S&P 500 Index and the Dow Jones Industrial Average also saw gains, indicating a favorable market session.

**5. Humana (HUM) Upgraded to Buy by Jefferies on Strong Growth Prospects**
- Source: GuruFocus | 20251205T170850 | Bullish | Relevance: 100%
- Jefferies has upgraded Humana (HUM) to a Buy rating, citing its effective Stars diversification strategy and strong growth prospects. The firm projects significantly higher earnings per share for 2026 and 2027 than consensus estimates, driven by expected Medicare Advantage membership expansion and improved plan quality. Despite potential margin pressures, Humana's strategic focus on higher-rated plans and robust financial health position it well for future profitability.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Jefferies | $313 | $253 | +24% |
| 2025-11-25 | Barclays | $234 | $245 | -4% |
| 2025-11-10 | Truist Securiti | $285 | $300 | -5% |
| 2025-11-07 | Deutsche Bank | $231 | $250 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Jefferies | up | Buy |
| 2025-11-25 | Barclays | main | Equal-Weight |
| 2025-11-10 | Truist Securiti | main | Hold |
| 2025-11-07 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.14M) |
| Sells | 6 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +6.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Analyst sentiment negative (3 target cuts vs 1 raises). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $31.1B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 20.7 |
| Current P/E | 15.1 |
| YoY Growth | -27.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.6% to 4.9% (+6.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 85th percentile. MRS_5 at 2.4% confirms short-term momentum alignment. AM_20 at 7.3% shows strong absolute momentum above own 20MA. Outperforming sector by 7.2pp, stock-specific strength. Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (3.92), confirming momentum. RSI neutral at 56. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.90% (CS: 85) | Strong |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | 3.92 | Bullish |
| vs SMA20 | 1.073x | Above |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 0.997x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $257.85
- **Stop Loss:** $238.99 (7.3% risk)
- **Target:** $295.57 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 26
- **Position Value:** $6,704.10
- **Portfolio %:** 6.70%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*